Eric Joseph
Stock Analyst at JP Morgan
(2.01)
# 3,088
Out of 5,053 analysts
124
Total ratings
38.82%
Success rate
-6.91%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $30.30 | +61.72% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $21.65 | +112.47% | 4 | Oct 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $61.26 | +4.47% | 4 | Jun 3, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.53 | - | 5 | May 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $45 → $44 | $3.15 | +1,296.83% | 3 | May 9, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $7.11 | -1.55% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $72.48 | -7.56% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.33 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.62 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $12.25 | +144.90% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $5.37 | +160.71% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $62.73 | +13.18% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $18.10 | +109.94% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $4.16 | +452.88% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $7.05 | +141.13% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $6.17 | +240.36% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $11.51 | -13.12% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.37 | +994.89% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.34 | +156.41% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $4.51 | +121.73% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $14.06 | -21.76% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $54.15 | -24.28% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $17.68 | +465.61% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.55 | +811.58% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.33 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $19.12 | -42.47% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $11.80 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $5.44 | +2,105.88% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $6.89 | +4,257.30% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.60 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.32 | +581.82% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.67 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $4.36 | +863.30% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $2.53 | +413.83% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.51 | +2,039.25% | 3 | Nov 14, 2018 |
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $30.30
Upside: +61.72%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $21.65
Upside: +112.47%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $61.26
Upside: +4.47%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.53
Upside: -
Rocket Pharmaceuticals
May 9, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $3.15
Upside: +1,296.83%
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $7.11
Upside: -1.55%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $72.48
Upside: -7.56%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.33
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.62
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $12.25
Upside: +144.90%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $5.37
Upside: +160.71%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $62.73
Upside: +13.18%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $18.10
Upside: +109.94%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $4.16
Upside: +452.88%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $7.05
Upside: +141.13%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $6.17
Upside: +240.36%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $11.51
Upside: -13.12%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.37
Upside: +994.89%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.34
Upside: +156.41%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $4.51
Upside: +121.73%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $14.06
Upside: -21.76%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $54.15
Upside: -24.28%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $17.68
Upside: +465.61%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.55
Upside: +811.58%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.33
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $19.12
Upside: -42.47%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $11.80
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $5.44
Upside: +2,105.88%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $6.89
Upside: +4,257.30%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $6.60
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.32
Upside: +581.82%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.67
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $4.36
Upside: +863.30%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $2.53
Upside: +413.83%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.51
Upside: +2,039.25%